Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 3Sarcoma, Alveolar Soft Part 1Recurrence 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × atropine sulfate-diphenoxylate hydrochloride drug combination × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡